A carregar...
HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry
BACKGROUND: Maraviroc (MVC) and other CCR5 antagonists are HIV-1 entry inhibitors that bind to- and alter the conformation of CCR5, such that CCR5 is no longer recognized by the viral gp120 envelope (Env) glycoproteins. Resistance to CCR5 antagonists results from HIV-1 Env acquiring the ability to u...
Na minha lista:
Main Authors: | , , , , , , , , , |
---|---|
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
BioMed Central
2011
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3217884/ https://ncbi.nlm.nih.gov/pubmed/22054077 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1742-4690-8-89 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|